Summer Street Starts Harvard Apparatus Regenerative Technology (HART) at Buy

Summer Street initiates coverage on Harvard Apparatus Regenerative Technology (NASDAQ: HART) with a Buy rating and a price target of $24.00.

Analyst Mark Landy comments, "HART has developed, perfected, and patented a novel approach for growing human organs to help address the increasing global shortage of organs available for transplant. The final version of the company’s lead product, the HART-Trachea, has been implanted five times in humans with great success and will be advanced into pivotal clinical trials later this year. When approved in the EU in 2017 and in the US in 2018, the HART-Trachea will be used to treat patients with tracheal abnormalities, tracheal cancer, and severe tracheal trauma."

For an analyst ratings summary and ratings history on Harvard Apparatus Regenerative Technology click here. For more ratings news on Harvard Apparatus Regenerative Technology click here.

Shares of Harvard Apparatus Regenerative Technology closed at $8.87 yesterday.

You May Also Be Interested In

• Craig-Hallum Assumes DiaMedica Therapeutics Inc. (DMAC) at Buy
• East West Bancorp (EWBC) PT Raised to $90 at BofA Securities
• Tesla (TSLA) soars on Q1 print